Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Cyclacel Pharma (CYCC) Tops Q4 EPS by 6c
March 24, 2015 4:18 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.20), $0.06 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $299 thousand, versus $247 thousand reported last year.
Cyclacel reported Q413 loss of $0.21 per share.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More